Clinical Determinants of Specialist-Optimized Parkinson's Disease Pharmacotherapy.
Nair Swathy Surendran SS, Prasad Shweta S, Holla Vikram V VV, Nagaraj Tarunya T et al.
Pharmacological management of Parkinson's disease (PD) is guided by several variables which significantly influence treatment decisions and therapeutic outcomes. This study aims to determine prescription patterns and clinical determinants for optimizing drug treatment of PD in a resource-limited setting by movement disorder specialists at a tertiary care center. In this prospective single-center study, demographic, clinical, and treatment details were recorded at the time of recruitment. The cohort was subclassified for evaluation of the treatment profile based on age at onset (AAO), early-onset PD (EOPD) and late-onset PD (LOPD); motor subtype, tremor-dominant PD (TDPD); postural instability and gait dysfunction (PIGD); indeterminate, age at evaluation; and disease duration. A total of 379 patients were recruited at a mean age of 54.17 ± 11.18 years and 6.14 ± 4.21 years of illness. Levodopa-carbidopa was universally prescribed (>92%). EOPD was more likely to receive dopamine agonists (DAs) (68.78% vs. 42.53%, P < 0.001), amantadine (28.29% vs. 17.24%, P = 0.014), and trihexyphenidyl (30.73% vs. 10.92%, P < 0.001) than LOPD. The PIGD subtype had a significantly higher usage of controlled-release levodopa-carbidopa DA, and amantadine compared TDPD. Younger patients received more DA and trihexyphenidyl; treatment complexity increased with disease duration, particularly with DA and amantadine. In conclusion, optimization of prescription patterns in PD is influenced by age, AAO, and motor phenotype. Levodopa-carbidopa is the mainstay of therapy, with younger patients more often receiving adjuncts such as dopamine agonists or amantadine, while older or advanced cases rely mainly on levodopa-based regimens. These findings underscore the need for individualized, phenotype-specific treatment strategies in PD management.